TriSalus Life Sciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TriSalus Life Sciences, Inc. (TLSI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.62M, a 3.93% increase year-over-year.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.47M, a 52.59% increase year-over-year.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.37M, a 159.31% increase year-over-year.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.52M, a 97.41% increase year-over-year.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.76M, a 79.29% increase from fiscal 2024.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.44M, a 288.09% increase from fiscal 2023.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.40M, a 280.98% increase from fiscal 2022.
- TriSalus Life Sciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $368.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.62M 10-Q · filed 2026-08-06 | $5.09M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.47M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $9.76M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $3.37M 10-Q · filed 2025-11-13 | $5.89M derived: sum of 2 quarters · filed 2026-08-06 | $7.51M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $2.52M 10-Q · filed 2026-08-06 | $4.14M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $1.62M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $5.44M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $1.30M 10-Q · filed 2025-11-13 | $1.38M 10-Q · filed 2024-11-14 | $2.58M derived: sum of 2 quarters · filed 2025-11-13 | $3.66M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.27M 10-Q · filed 2025-11-13 | $2.36M derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $1.09M 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $1.40M 10-K/A · filed 2025-05-30 | ||||
| 2023-09-30 | $259.00K 10-Q · filed 2024-11-14 | $328.00K derived: sum of 2 quarters · filed 2024-11-14 | $401.00K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $69.00K 10-Q · filed 2024-11-14 | $142.00K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $73.00K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $368.00K 10-K · filed 2024-04-11 | ||||
| 2022-09-30 | $119.00K 10-Q · filed 2023-11-14 | $189.00K derived: sum of 2 quarters · filed 2023-11-14 | $251.00K derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $70.00K 10-Q · filed 2023-11-14 | $132.00K derived: sum of 2 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $62.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |